Shona T. Dougherty, MB, ChB, PhD

Shona T. Dougherty, MB, ChB, PhD

Clinic Director

Professor

Contact Information

Office Location: 
3838 N Campbell Ave, BLDG 2
Phone Number: 
520-694-7236
Fax: 
520-694-0197

Background

Dr. Dougherty earned her medical degree from the University of Edinburgh, Edinburgh, Scotland in 1985, and her doctorate from the University of British Columbia, Vancouver, British Columbia, Canada in 1995. She was assistant professor at UCLA from 1996-2003, where she supervised the prostate seed brachytherapy program, as well as the TBI (total body irradiation) service. Dr. Dougherty joined the Arizona Cancer Center in August 2003, and has since been a zealous educator, directing the Radiation Oncology Residency Training Program since 2004.

Dr. Dougherty specializes in prostate cancer, and as an expert in prostate brachytherapy, presides over the prostate seed implant program at UAHN. Her primary interests include genitourinary cancers such as prostate, bladder and kidney disease. Additionally, she focuses on radiotherapy for gynecologic cancers, including various applications of brachytherapy. As a research scientist, Dr. Dougherty is currently involved in database construction to assess retrospective prostate radiotherapy outcomes.  Dr. Dougherty became the departmental clinic director in 2003, and joined Dr. Baldassarre Stea (head of Radiation Oncology) as associate head of the department in 2008.  She serves on several committees throughout the organization overseeing physician credentialing, resident education, quality assurance and program development. 

Professional Affiliations: 
  • AMA (American Medical Association)
  • BMA (British Medical Association)
  • AACR (American Association for Cancer Research)
  • ASTRO (American Society for Therapeutic Radiation Oncology)
  • CARO (Canadian Association for Radiation Oncology)
  • ABS (American Brachytherapy Society)
Honors: 
  • Distinction Award-Psychiatry, University of Edinburgh, Scotland
  • Distinction Award-Community Medicine, University of Edinburgh, Scotland
  • Selected to attend the Sixth National Cancer Institute of Canada Course in Oncology, McMaster University, Hamilton, Ontario, Canada
  • National Cancer Institute of Canada Fellowship Award
  • Canadian Association of Radiation Oncologists Residents Research Award (1992)
  • Canadian Association of Radiation Oncologists Residents Research Award (1993)
  • Listed in "The Best Doctors in America," 2009

Clinical

Board Certifications: 

Board eligible for Radiation Oncology Fellow of the Royal College of Physicians and Surgeons of Canada USMLE I USMLE II LMCC (Licentiate of the Medical Council of Canada) CSA (Clinical Skills Assessment) ECFMG Certificate

Clinical Practice Sites: 
The University of Arizona Cancer Center - Orange Grove
Radiation Oncology
The University of Arizona Medical Center - University Campus

Education

Doctorate: 
University of British Columbia, Vancouver, British Columbia, Canada
Fellowship: 
Royal College of Physicians and Surgeons of Canada
Medical School: 
University of Edinburgh, Edinburgh, Scotland
Undergraduate School: 
University of Edinburgh, Edinburgh, Scotland

Research

Selected Publications: 
Hayes, G.M., Dougherty, S.T., Davis, P.D. and Dougherty, G.J. Molecular mechanisms regulating the tumor targeting potential of splice-activated gene expression. Cancer Gene Therapy 11:797-807, 2004.
 
Dougherty, S.T., Davis, P.D. and Dougherty, G.J. Vascular-targeted cancer gene therapy. Expert Opinion in Biology Therapy 4(12):1911-1920, 2004.
 
Dougherty, G.J., Davis, P.D. and Dougherty, S.T. Development of vascular targeted cancer gene therapy. In: Vascular Targeted Therapies in Oncology, Siemann, D. (Ed). Chapter 14, p 247-259, John Wiley and Sons, Inc., New York, 2006.
 
Pawar, S.C., Dougherty, S., Pennington, M.E., Demetriou, M.C., Stea, B.D., Dorr, R.T. and Cress, A. Alpha 6 integrin Cleavage: Sensitizing human prostate cancer to ionizing radiation. International Journal of Radiation Biology 83(11):761-767, 2007.
 

Dougherty, G.J. and Dougherty, S.T.  Exploiting the tumor microenvironment in the development of targeted cancer gene therapy. Cancer Gene Therapy 16(3) 279-290, 2009.

Dougherty, S.T., Walker, S., Davis, P.D. and Dougherty, G.J. The novel vascular disrupting agent ANG501 induces cell cycle arrest and enhances endothelial cell sensitivity to radiation. Cancer Growth and Metastasis 2: 1-10, 2009.
 
Dougherty, S.T. and Dougherty, G.J. A cancer gene therapy approach that targets tumor-associated hyaluronan. Cancer Growth and Metastasis 2: 29-43, 2009.
 
Dougherty, G.J. and Dougherty, S.T. Vascular-targeted cancer gene therapy. In: ‘The Tumor Microenvironment’ Dietmar W. Siemann (Ed.) 401-419, John Wiley and Sons, Inc., New York. 2011.

Dougherty, S.T. and Dougherty, G.J. Mechanisms conferring resistance to pro-apoptotic cancer gene therapy. Journal of Cell Death 4: 19-30, 2011.

Skrepnik, T. and Dougherty, S. Principles of radiation therapy for uterine cancers. In: “Multidisciplinary Approach to Cancer of the Uterine Corpus” Odunsi (Ed.) Chapter 10, p67-72, 2013 

Clinical Studies

Titlesort descending Description Cancer Area Cancer Type Trial Status
1606636273 – NRG-GY006

NCT02466971 A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer

Comppare

NCT03561220 A Prospective Comparative Study of Outcomes with Proton and Photon Radiation in Prostate Cancer

NRG-GU002

NCT03070886: Phase II-III trial of adjuvant radiotherapy and androgen deprivation following radical prostatectomy with or without adjuvant Docetaxel

NRG-GU007

NCT04037254: Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I)

S1802

NCT03678025 Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer